Biogen Inc. - Common Stock — 현금 흐름 (NASDAQ:BIIB)

Financials

영업활동으로 인한 현금 4.23 B3.64 B1.38 B1.55 B2.88 B2.2 B 2.59 B 투자 활동으로 인한 현금 -608.6 M-563.7 M1.58 B-4.1 B-799.2 M-1.37 B -1.53 B 재무활동으로 인한 현금 -5.27 B-2.09 B-1.75 B149.3 M-683.5 M-301.9 M -322.7 M 잉여 현금 흐름 4.23 B3.64 B1.38 B1.55 B2.88 B2.02 B 2.4 B

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

BIIB

Financials

Biogen Inc. - Common Stock

뉴스

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach (NASDAQ:IONS)

Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Are Wall Street Analysts Bullish on Biogen Stock?

Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth

Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.

Stock Market Today: Nasdaq Charges Higher; Hot Nvidia Rival Surges On Debut (Live Coverage)